Filing Details

Accession Number:
0001562180-18-004219
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-10-15 17:57:10
Reporting Period:
2018-10-15
Accepted Time:
2018-10-15 17:57:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1560241 G1 Therapeutics Inc. GTHX Pharmaceutical Preparations (2834) 263648180
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1706853 Rajesh Malik C/O G1 Therapeutics, 79 Tw Alexander Dr.
4501 Research Commons, Suite 100
Research Triangle Park NC 27709
Ch. Medical Officer & Svp R&D No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-10-15 3,776 $4.17 12,176 No 4 M Direct
Common Stock Disposition 2018-10-15 943 $40.80 11,233 No 4 S Direct
Common Stock Disposition 2018-10-15 2,833 $42.01 8,400 No 4 S Direct
Common Stock Acquisiton 2018-10-15 6,300 $0.39 14,700 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2018-10-15 3,776 $0.00 3,776 $4.17
Common Stock Stock Option (Right to Buy) Disposition 2018-10-15 6,300 $0.00 6,300 $0.39
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
73,071 2026-05-10 No 4 M Direct
97,444 2024-07-11 No 4 M Direct
Footnotes
  1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
  2. The price represents the weighted average price with a low of $40.60 and a high of $40.99. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 and 3 to this Form 4.
  3. The price represents the weighted average price with a low of $41.95 and a high of $42.29.
  4. The shares underlying this option vested as to 25% of the shares on May 10, 2017, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
  5. All shares underlying this option have vested.